4 conclusion
In conclusion, acipimox is a well-tolerated lipid-lowering agent that
has been increasingly recommended in recent years. Although routine
liver function monitoring is not recommended for patients receiving
acipimox because hepatotoxicity is rarely caused by the drug, a high
degree of vigilance is required of clinicians to diagnose
acipimox-induced hepatotoxicity. MgIg is a viable therapeutic option for
DILI due to its cytoprotective and immunomodulatory effects.